CS Diagnostics Taps UAE Giants for Global MEDUSA Hygiene Launch

CHEYENNE, Wyo. – January 29, 2026 – CS Diagnostics Corp. (OTCQB: CSDX), a medical technology company, has solidified its path to global commercialization by securing strategic manufacturing partnerships with two of the UAE's leading production firms. The agreements with Emirate Wet Wipes LLC and Gulf Centre Group Factory are set to accelerate the full-scale production and international launch of MEDUSA SDP, the company's next-generation line of medical-grade disinfectant wipes and liquids.

This move marks a pivotal transition for CS Diagnostics, shifting the MEDUSA SDP platform from the development phase directly into revenue-ready production. The partnerships are designed to establish a robust and scalable supply chain ahead of a planned multi-region launch across the GCC and Europe, targeting the healthcare, institutional, and consumer hygiene markets.

A Strategic Leap to Commercialization

For CS Diagnostics, these agreements represent more than just a production contract; they are a cornerstone of the company's commercial strategy. By locking in dedicated manufacturing capacity, the company aims to effectively address the anticipated global demand for advanced infection prevention solutions. Management has framed the deals as a critical milestone that provides operational flexibility and a clear runway toward generating revenue from its hygiene division.

The company operates on a dual-focus platform, balancing its efforts between the MEDUSA hygiene solutions and its oncology-focused product, CS Protect-Hydrogel, a tissue spacer used in prostate cancer radiotherapy. This latest development firmly propels the MEDUSA platform into the commercial spotlight, signaling a new phase of growth and market engagement for the Wyoming-based firm.

“Securing these strategic manufacturing partnerships is a pivotal step in advancing MEDUSA SDP from development into full-scale commercial production,” said Mohammad Essayed, Chief Financial Officer of CS Diagnostics Corp., in the company's official announcement. “By aligning with experienced, quality-driven manufacturers, we are establishing the operational foundation needed to meet rising global demand for infection prevention and hygiene solutions.”

Leveraging Manufacturing Powerhouses in the GCC

A closer look at the chosen partners reveals a deliberate strategy focused on quality, scale, and regional expertise. Emirate Wet Wipes LLC, contracted to produce the MEDUSA SDP disinfectant wet wipes, is the largest manufacturer of its kind in the GCC region. Established in 2001, the Dubai-based company boasts a state-of-the-art facility and a portfolio of certifications including ISO 9001, GMP (Good Manufacturing Practices), and HACCP. Its extensive experience includes producing for major international brands like Dettol and supplying large-scale clients such as Emirates Airlines, underscoring its capacity to meet stringent quality and volume requirements for medical-grade products.

Meanwhile, the production of bulk liquid hygiene and disinfectant formulations, including 500ml bottles and 5-liter commercial formats, will be handled by Gulf Centre Group Factory. With over 35 years in the industry, the Abu Dhabi-based group is a major player in professional cleaning and hygiene solutions. Its manufacturing arms, such as Gulf Center Cosmetics Manufacturing LLC (GCCM), hold GMP-ISO 22716 and ISO 9001:2015 certifications, specializing in personal and home care products, including hand sanitizers. This partnership ensures CS Diagnostics has access to compliant, high-volume production for its liquid disinfectant line, crucial for servicing hospitals, clinics, and large institutional clients.

By partnering with established UAE manufacturers, CS Diagnostics not only secures production capacity but also gains a strategic foothold in the rapidly growing GCC market, leveraging local expertise and aligning with the region's push for increased domestic manufacturing and supply chain resilience.

Meeting a Persistent Global Need

The launch of MEDUSA SDP is timed to address a sustained global focus on hygiene and infection control. The demand for effective disinfectants, particularly in clinical settings, remains a top public health priority. The ongoing battle against hospital-acquired infections (HAIs), which affect millions of patients and add significant costs to healthcare systems worldwide, creates a constant need for innovative and reliable hygiene solutions.

The market for disinfectants, which surged during the global pandemic, has stabilized at a new, higher baseline of awareness among institutions and consumers alike. Market trends indicate continued growth, driven by rising healthcare expenditures, stringent regulatory environments in regions like Europe, and a growing consumer preference for products that offer medical-grade protection. CS Diagnostics is positioning MEDUSA SDP to capture a share of this expanding market by offering a versatile product line suitable for high-stakes hospital environments as well as everyday consumer use.

Navigating a Competitive Landscape

CS Diagnostics enters a fiercely competitive arena dominated by established global giants such as 3M, Ecolab, Reckitt Benckiser, and Diversey. These companies have extensive product portfolios, deep market penetration, and significant brand recognition. To carve out a niche, MEDUSA SDP will need to demonstrate clear points of differentiation.

Success will likely hinge on several factors. First, proving superior efficacy—such as faster kill times against a broad spectrum of pathogens or better material compatibility—will be essential to gain traction in the medical community. Second, the reliability of the new supply chain will be critical; leveraging the robust manufacturing capabilities of its UAE partners could provide a competitive advantage in logistics and consistent availability, especially within the GCC. Finally, the company's ability to execute a multi-channel distribution strategy across hospitals, retail chains, and e-commerce platforms will determine its reach and ability to challenge incumbents.

The company’s forward-looking plans, which include the potential introduction of biodegradable and dissolving hygiene products, suggest an awareness of another key market trend: sustainability. By combining medical-grade performance with a modern approach to logistics and product innovation, CS Diagnostics is betting it can make a significant impact on the global stage of infection prevention.